Editas Medicine (EDIT) Share-based Compensation (2015 - 2025)

Editas Medicine (EDIT) reported Share-based Compensation of $2.2 million for Q3 2025, down 53.6% year-over-year from $4.8 million in Q3 2024, and down 16.37% on a QoQ basis from $2.7 million in Q2 2025.

Editas Medicine (EDIT) has 11 years of Share-based Compensation data on file, last reported at $2.2 million in Q3 2025.

  • Quarterly Share-based Compensation fell 53.6% year-over-year to $2.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $11.9 million (down 47.71% YoY) and the FY2024 annual result came in at $21.4 million, up 8.18% from the prior year.
  • Share-based Compensation declined to $2.2 million in Q3 2025 per EDIT's latest filing, from $2.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $13.5 million in Q2 2021 and bottomed at $2.2 million in Q3 2025.
  • The 5-year median for Share-based Compensation is $5.3 million (2023), against an average of $6.4 million.
  • The widest annual swing landed in 2021, when Share-based Compensation soared 149.7%; it then tumbled 60.73% in 2025.
  • Tracing EDIT's Share-based Compensation over 5 years: stood at $7.7 million in 2021, then dropped by 29.95% to $5.4 million in 2022, then decreased by 0.35% to $5.3 million in 2023, then retreated by 24.79% to $4.0 million in 2024, then slumped by 44.58% to $2.2 million in 2025.
  • Per Business Quant, the three latest EDIT Share-based Compensation figures stand at $2.2 million (Q3 2025), $2.7 million (Q2 2025), and $3.0 million (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 892,057.00
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 305,000.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 166.40 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 257.40 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 70.15 Mn
10 Editas Medicine 338.62 Mn 338.62 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 2.23 Mn
Sep 30, 2025 2.23 Mn
Jun 30, 2025 2.66 Mn
Jun 30, 2025 2.66 Mn
Mar 31, 2025 2.98 Mn
Mar 31, 2025 2.98 Mn
Dec 31, 2024 4.02 Mn
Dec 31, 2024 4.02 Mn
Sep 30, 2024 4.80 Mn
Sep 30, 2024 4.80 Mn
Jun 30, 2024 5.01 Mn
Jun 30, 2024 5.01 Mn
Mar 31, 2024 7.59 Mn
Mar 31, 2024 7.59 Mn
Dec 31, 2023 5.35 Mn
Dec 31, 2023 5.35 Mn
Sep 30, 2023 4.73 Mn
Sep 30, 2023 4.73 Mn
Jun 30, 2023 5.22 Mn
Jun 30, 2023 5.22 Mn
Mar 31, 2023 4.51 Mn
Mar 31, 2023 4.51 Mn
Dec 31, 2022 5.36 Mn
Dec 31, 2022 5.36 Mn
Sep 30, 2022 5.88 Mn
Sep 30, 2022 5.88 Mn
Jun 30, 2022 6.62 Mn
Jun 30, 2022 6.62 Mn
Mar 31, 2022 11.43 Mn
Mar 31, 2022 11.43 Mn
Dec 31, 2021 7.66 Mn
Dec 31, 2021 7.66 Mn
Sep 30, 2021 10.01 Mn
Sep 30, 2021 10.01 Mn
Jun 30, 2021 13.53 Mn
Jun 30, 2021 13.53 Mn
Mar 31, 2021 12.20 Mn
Mar 31, 2021 12.20 Mn
Dec 31, 2020 5.67 Mn
Dec 31, 2020 5.67 Mn
Sep 30, 2020 5.85 Mn
Sep 30, 2020 5.85 Mn
Jun 30, 2020 5.42 Mn
Jun 30, 2020 5.42 Mn
Mar 31, 2020 6.22 Mn
Mar 31, 2020 6.22 Mn
Dec 31, 2019 6.34 Mn
Dec 31, 2019 6.34 Mn
Sep 30, 2019 6.56 Mn
Sep 30, 2019 6.56 Mn
Jun 30, 2019 6.49 Mn
Jun 30, 2019 6.49 Mn
Mar 31, 2019 7.86 Mn
Mar 31, 2019 7.86 Mn
Dec 31, 2018 6.35 Mn
Dec 31, 2018 6.35 Mn
Sep 30, 2018 6.70 Mn
Sep 30, 2018 6.70 Mn
Jun 30, 2018 7.02 Mn
Jun 30, 2018 7.02 Mn
Mar 31, 2018 6.53 Mn
Mar 31, 2018 6.53 Mn
Sep 30, 2017 4.47 Mn
Sep 30, 2017 4.47 Mn
Jun 30, 2017 5.02 Mn
Jun 30, 2017 5.02 Mn
Mar 31, 2017 5.80 Mn
Mar 31, 2017 5.80 Mn
Dec 31, 2016 3.78 Mn
Dec 31, 2016 3.78 Mn
Sep 30, 2016 3.69 Mn
Sep 30, 2016 3.69 Mn
Jun 30, 2016 5.20 Mn
Jun 30, 2016 5.20 Mn
Mar 31, 2016 4.21 Mn
Mar 31, 2016 4.21 Mn
Dec 31, 2015 1.95 Mn
Dec 31, 2015 1.95 Mn
Sep 30, 2015 1.06 Mn
Sep 30, 2015 1.06 Mn
Jun 30, 2015 440,000.00
Jun 30, 2015 440,000.00
Mar 31, 2015 65,000.00
Mar 31, 2015 65,000.00